Marina Litvin M.D.

Assistant Professor of Medicine

Marina Litvin MD, is an Assistant Professor of Medicine in the Washington University School of Medicine, in St. Louis, MO. She received her medical degree from the University of Missouri, Columbia, and completed her Internal Medicine Residency and Endocrinology Fellowship training at Barnes Jewish Hospital/Washington University School of Medicine. Dr. Litvin's clinical interests include Cystic Fibrosis Related Diabetes (CFRD) and Cystic Fibrosis Related Endocrine Dysfunction, as well as the emerging phenomenon of obesity in patients with Cystic Fibrosis. In 2015, Dr. Litvin, and Dr. Rosenbluth, the Director of the Adult Cystic Fibrosis Clinic at the Washington University School of Medicine, created a combined, multidisciplinary Cystic Fibrosis - CFRD Clinic. Through the three year partnership, and a QI initiative, Dr. Litvin helped to improve glycemic control in this patient population, and has helped to significantly improve the rate of oral glucose tolerance testing, identifying patients with new diagnosis of CFRD, as well as those with abnormal glucose tolerance (pre-diabetes). Dr. Litvin is also working on an initiative to pilot continuous glucose monitoring (CGM) in the hospital Cystic Fibrosis Unit, to improve glycemic control and glycemic variability by providing real-time continuous assessment of glucose and real-time insulin management. Dr. Litvin received the Cystic Fibrosis Foundation's EnVision grant award for clinical care and research in Endocrine and Diabetes Care in patients with Cystic Fibrosis. This award (2016-2019) provides a clinical/research mentor, and allows for extra time and resources to focus on Cystic Fibrosis Research and care of patients with Cystic Fibrosis Related Diabetes. Current Cystic Fibrosis Related Publications include: 1. Litvin M, Nwachukwu S. Cystic Fibrosis Related Diabetes: a Unique Challenge in Diabetes Care. Missouri Medicine. October 2016. 2. Litvin M, Rosenbluth D, Atkinson J, Zukoski J. Title: Lumacaftor/ivacaftor (Orkambi) Not Quite a Cure for Cystic Fibrosis Related Diabetes (CFRD). American Diabetes Association abstracts. June 2017. Published Abstract. 3. Litvin M, Rosenbluth D, Atkinson J, Zukoski J.Quality Improvement (QI): Systematic Approach to Increasing the Rate of Oral Glucose Tolerance Testing (OGTT) In Adult Patients with Cystic Fibrosis (CF). Poster presentation at NACFC 2017. 4. Litvin M. Cystic Fibrosis Related Diabetes: A Unique Challenge for the CF Provider. Short Course. NACFC 2017.

Appearances